SMi Group Release New Interview with Leading Allergist, Professor Kimihiro Okubu

Share Article

Nippon Medical Speak to SMi Group in the Run to their Keynote Address at Allergies 2016

An Interview with Nippon Medical School

An Interview with Nippon Medical School

"Every allergist wants to know the biomarker for adequate evaluation of clinical symptoms" - Professor Kimihiro Okubu

SMi’s 3rd annual Allergies conference returns to London this July and is thrilled to have leading allergist Professor Kimihiro Okubu from Nippon Medical School, as one of the featured speakers for 2016.

Kimihiro Okubu is an ENT surgeon and is currently responsible for clinical research and the development of new drugs at Nippon Medical School where he is a Chair and Professor. He works alongside leading pharmaceutical companies on antihistamines, antileukotoriens, anti-DP receptors, and immunotherapy for the treatment of allergic rhinitis.

In the run-up to his address at Allergies 2016, SMi Group caught up with Professor Okubu to discuss current developments in treatment and diagnosis.

When asked about current challenges in treatment he said:

“I believe the changing of strategy for treatment of allergic rhinitis is coming also in Japan. Every allergist and physician want to know how to use the SCIT or SLIT in the period of allergic march from children to adult.”

On current industry developments, he commented:

“I am realizing the development of allergy diagnosis is fewer than the development of allergy treatment. Molecular diagnosis and epitope diagnosis is evaluated but there are not so good correlation to clinical symptoms.”

The full interview is available to read in the event download center at

Hear more from Professor Kimihiro Okubu at Allergies 2016 in his keynote presentation on sublingual immunotherapy for cedar pollinosis and mite allergies. A detailed agenda and speaker line-up is also available at

Allergies 2016
Conference: 6th & 7th July | Interactive Workshop: 5th July
Holiday Inn Kensington Forum, London, UK

Sponsored by: Allergy Therapeutics, DBV Technologies, Indoor Biotechnologies and Inflamax Research

--- end ---

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Teri Arri
SMi Group
+44 2078276162
Email >
since: 10/2011
Follow >
Visit website